Targeting cellular energy metabolism to treat chronic disease
Therapeutic interventions aimed at restoring cellular metabolic and energy homeostasis are promising approaches for treating a wide range of serious chronic diseases; these include common disorders - in particular, Type 2 diabetes and non-alcoholic steatohepatitis (NASH), as well as rare diseases such as adrenoleukodystrophy (ALD) among others. We have focused our research and development activities on high value targets that are important in the regulation of cellular metabolic and energy homeostasis:
- Mitochondrial respiratory chain (MRC)
- Direct activation of adenosine monophosphate-activated protein kinase (AMPK)
- Leveraging non-genomic pathways modulated by thiazolidinediones (TZDs)
Mitochondria - The Cell’s Energy Powerhouse
The mitochondrion is the power center of the cell generating energy through the production of adenosine triphosphate, or ATP, the primary unit of cellular energy, by oxidizing nutrients such as glucose and lipids, and contributing to the regulation of cellular and systemic energy balance.
Mitochondrial dysfunction is a prominent feature of the pathophysiology of many metabolic diseases including Type 2 diabetes, NASH, obesity and also rare disorders (in particular inherited mitochondrial diseases). Overnutrition and a sedentary lifestyle are leading causes of mitochondrial dysfunction in the context of common metabolic disorders. This disequilibrium in the cellular energy balance leads to several adverse sequelae including inadequate ATP production and an increase in the production of reactive oxygen species, or ROS, from the mitochondrial respiratory chain. Such effects can lead to insufficient insulin secretion in response to glucose and to impaired insulin sensitivity.
Poxel's most advanced molecule, Imeglimin, improves mitochondrial function by modulating mitochondrial respiratory chain (MRC) complex activities leading to a dual effect to improve pancreatic islet b-cell function and to enhance insulin action (reduce insulin resistance) as illustrated below.
Imeglimin's Dual Mode of Action is Driven by Targeting Mitochondrial Dysfunction
(*) Reactive oxygen species. (#) mitochondrial permeability transition pore.
Adapted from: Hallakou-Bozec et al, Mechanism of action of Imeglimin – a novel therapeutic agent for type 2 diabetes; Diabetes Obes Metab 2021, doi.org/10.1111/dom.14277
AMP Kinase – A Key Cellular Energy Sensor
The AMP activated protein kinase (AMPK) enzyme complex (consisting of 3 distinct subunits) is major energy sensor whose role is to maintain cellular energy homeostasis. AMPK is activated by several stimuli including caloric restriction and exercise and is inhibited by overnutrition and inflammation. AMPK activation enhances catabolic processes and down-regulates anabolic pathways. Among its main effects are induction of lipid metabolism, attenuation of inflammation and inhibition of cell death in certain contexts.
The AMP Kinase Enzyme Complex Regulates Several Cellular Pathways
Poxel's small molecule direct AMPK activators have a wide range of effects in both cellular and in vivo model systems (including inhibition of de novo lipogenesis, reductions in pro-inflammatory pathways and insulin sensitization). Our lead AMPK activator, PXL770, has demonstrated translation of several metabolic effects to humans based on clinical Phase 1-2a trials. Direct AMPK activation is being pursued as an approach to several conditions including NASH, adrenoleukodystrophy and others.
Non-Genomic Pathways Modulated by Thiazolidinedione (TZDs)
Thiazolidinediones (TZDs) are a class of small molecules that have been traditionally linked to induction of gene transcription via their effects to activate peroxisome proliferator-activated receptor gamma (PPARg). These molecules include pioglitazone, a widely prescribed medicine for Type 2 diabetes. TZDs also have non-genomic (non-PPAR) actions that include modulating the mitochondrial pyruvate carrier (MPC) and other pathways. PPARg activation by TZDs is known to cause weight gain, fluid retention (edema) and an increase in risk of bone fractures. By modifying TZDs with deuterium – deuterium-modified TZDs (D-TZDs), Poxel has discovered novel molecules which lack significant PPARg activity but retain selective non-genomic actions. MPC is a cellular fuel gatekeeper; its inhibition promotes fat utilization, increases insulin sensitivity, and decreases inflammation.
Deuterium Modified TZDs (D-TZDs) Function via Non-Genomic Pathways
The lead D-TZD, PXL065, is the deuterium-modified R-stereoisomer of pioglitazone. It selectively acts through non-genomic pathways to effectively treat NASH and reduce inflammation in preclinical models with little or no observed PPARg activation associated adverse effects. Preclinical, Phase 1 and Phase 2 results to date, supports Poxel hypothesis that PXL065 may have a better therapeutic profile than pioglitazone for NASH. D-TZDs also have strong potential in adrenoleukodystrophy and other rare metabolic disorders.